Creative Commons source reading · Alzheimer’s disease and related dementias
Diagnostic Accuracy of a Plasma Phosphorylated Tau 217 Immunoassay for Alzheimer Disease Pathology.
Nicholas J Ashton; Wagner S Brum; Guglielmo Di Molfetta; Andrea L Benedet; Burak Arslan; Erin Jonaitis; Rebecca E Langhough; Karly Cody; Rachael Wilson; Cynthia M Carlsson; Eugeen Vanmechelen; Laia Montoliu-Gaya; Juan Lantero-Rodriguez; Nesrine Rahmouni; Cecile Tissot; Jenna Stevenson; Stijn Servaes; Joseph Therriault; Tharick Pascoal; Alberto Lleó; Daniel Alcolea; Juan Fortea; Pedro Rosa-Neto; Sterling Johnson; Andreas Jeromin; Kaj Blennow; Henrik Zetterberg
Originally published in JAMA neurology · 2024-03-01
From the article
Selected source text. JournalOS removes markup and shortens excerpts where indicated. The full article provides the complete context.
Abstract
Importance Phosphorylated tau (p-tau) is a specific blood biomarker for Alzheimer disease (AD) pathology, with p-tau217 considered to have the most utility. However, availability of p-tau217 tests for research and clinical use has been limited. Expanding access to this highly accurate AD biomarker is crucial for wider evaluation and implementation of AD blood tests. Objective To determine the utility of a novel and commercially available immunoassay for plasma p-tau217 to detect AD pathology and evaluate reference ranges for abnormal amyloid β (Aβ) and longitudinal change across 3 selected cohorts. Design, setting, and participants This cohort study examined data from 3 single-center observational cohorts: cross-sectional and longitudinal data from the Translational Biomarkers in Aging and Dementia (TRIAD) cohort (visits October 2017-August 2021) and Wisconsin Registry for Alzheimer's Prevention (WRAP) cohort (visits February 2007-November 2020) and cross-sectional data from the Sant Pau Initiative on Neurodegeneration (SPIN) cohort (baseline visits March 2009-November 2021).
Methods
TRIAD included 268 participants who had no cognitive impairment (134 individuals [50%]), MCI (63 [23.5%]), AD dementia (46 [17.2%]), and non-AD dementia (24 [9.0%]). The WRAP study26 included data on 323 participants, predominantly without cognitive impairment at the first plasma sample collection (no impairment, 309 [95.6%]; MCI, 12 [3.7%]; AD dementia, 2 [0.6%]). The SPIN cohort27 included 195 participants: controls without cognitive impairment (82 [42.1%]), individuals with MCI due to AD (72 [36.7%]), and individuals with AD dementia (41 [21.0%]).
Discussion
In 3 independent cohorts, this study presents the performance of a commercially available plasma assay targeting p-tau217. Our findings demonstrate high accuracy in identifying abnormal Aβ and tau pathologies, comparable with CSF measures and superior to brain atrophy assessments.
Conclusions
This study highlights the effectiveness of a commercially available plasma p-tau217 assay in identifying AD pathology. Our findings demonstrate the substantial reduction of confirmatory testing, by approximately 80%, by implementing a 3-range approach for Aβ positivity based on plasma p-tau217. These results emphasize the important role of plasma p-tau217 as an initial screening tool in the management of cognitive impairment by underlining those who may benefit from antiamyloid immunotherapies.
Editorial reading guide
- Was the evidence cross-sectional, longitudinal or experimental?
- How did the authors account for age, disease stage and differences among participants?
